Decitabine

地西他滨

Report date: 2026/04/24 20:01:59
NME

Base Information

Drug NameDecitabine
Drug Alias NameDezocitidine地西台宾Decitabinum地西他biDeoxycytidine +[15] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA (cytosine-5)-methyltransferase 1 inhibitors
TargetsDNA (cytosine-5)-methyltransferase 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)CycloplegiaSolid tumours +[54] 
Global Approved IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Approved Indications in ChinaMyelodysplastic Syndromes
Original Approved Country/TerritoryUnited States
Original Approved Date2006/05/02
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJanssen-Cilag International NvViMREX GmbHUniversity Of Rochester +[9] 
Inactive CompaniesUtah State UniversityCarelon ResearchRadboud University Medical Center +[24] 
Active IndicationsCycloplegiaSolid tumoursAnaphylaxis +[12] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)NeutropeniaMyeloproliferative Disorders +[42] 

Other Information

ATC CodeL01BC08
Related LinksWikipediaDrugBankKEGG